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Background
Immunotherapy has become an effective cancer therapy,
particularly in the case of checkpoint blockade and adop-
tive T cell therapy (ACT). ACT exploits the presence of
tumor-infiltrating lymphocytes (TIL) by exponentially
expanding their numbers ex vivo and re-infusing them
into the patient in an autologous setting. With the effec-
tiveness of TIL therapy already well established in multiple
Phase II studies in melanoma, there is a push to translate
it to other malignancies such as ovarian cancer (OvCa) [1].
Methods
The presence of TIL is correlated with greatly increased
survival in OvCa [2,3] suggesting that TIL effectively con-
trol the disease and provide a rationale to test TIL therapy
in this setting. To assess the feasibility, we characterized
the immune component of OvCa, explored the ability to
grow & expand TIL from tumor fragments, and tested
their functionality.
Results
Extensive flow cytometry analysis detected a robust, acti-
vated T cell infiltrate that can be grown from OvCa sam-
ples obtained pre- and post-chemotherapy. The addition
of an agonistic anti-41BB antibody to the cultures prefer-
entially increased CD8+ TIL outgrowth as well as favored
the expansion of NK cells. Importantly, success rate of
TIL growth was increased from 40% to 90% for cultures
grown without and with anti-41BB respectively. It was
established next that the CD3+ TIL initially grown with
anti-41BB could be rapidly expanded at least 1000 fold
over two weeks. Finally, the rapidly expanded T cells
exhibited anti-tumor capabilities in the context of re-
directed killing assays.
Conclusions
In conclusion, further flow cytometry analysis to identify
other agonistic and inhibitory targets is needed along with
additional in vitro and in vivo experiments. However, the
initial data suggest that TIL therapy for OvCa could be a
viable therapeutic option in the future.
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